Complete withdrawal of hepatitis B virus prophylaxis after liver transplantation in a recipient at high risk of recurrence
Complete withdrawal of hepatitis B virus prophylaxis after liver transplantation in a recipient at high risk of recurrence
复制标题
复发风险高的受者肝移植后完全停止乙型肝炎病毒预防
DOI：
--
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
叶于富
中科院分区：
文献类型：
--
作者：
叶于富
随着强效核糖核酸类似物的开发，对乙肝病毒相关性肝移植术后复发的终生联合预防的必要性受到了挑战。但是，在移植前表现出活跃的乙肝病毒复制的高复发风险患者中，尚未观察到完全停止乙肝预防措施。在此，我们描述了一例肝移植时HBeAg和HBVDNA阳性的患者，在应用乙肝免疫球蛋白(HBIG)和恩替卡韦3年后，完全停用了乙肝预防措施，并在长期的随访中没有显示出乙肝病毒复发。
With the potent nucleos (t) ide analogues developed, necessity of life-long combined prophylaxis against hepatitis B virus (HBV) recurrence after HBV-related liver transplantation has been challenged. But complete withdrawal of HBV prophylaxis has not been previously observed in patients at high recurrence risk who showed active HBV replication before transplant. Herein, we describe a patient with positive HBeAg and HBV-DNA at the time of liver transplantation, who experienced complete HBV prophylaxis withdrawal after 3 years’ application of hepatitis B immunoglobulin (HBIG) and entecavir, and showed no HBV recurrence during a long term of follow-up.